Gamaleya Research Institute of Epidemiology and Microbiology

Venezuela received 7 mn doses of Sputnik Light booster in the biggest one-time global delivery of the one-shot Russian vaccine

Retrieved on: 
Tuesday, December 21, 2021
Hospital, Sputnik V COVID-19 vaccine, Vaccination, Pericarditis, Gamaleya Research Institute of Epidemiology and Microbiology, Infection, Sputnik 1, Technology, Equity, RNA transfection, AstraZeneca, City, Vaccine, Epitope, Myocarditis, Ministry, Coronavirus, Gamaleya, VNA, Sputnik Light, Russian Direct Investment Fund, RDIF, Delta, Omicron

MOSCOW, Dec. 21, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) today announced 7 million doses of Sputnik Light booster against coronavirus have been shipped to Venezuela becoming the biggest one-time global delivery of the one-shot vaccine.

Key Points: 
  • MOSCOW, Dec. 21, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) today announced 7 million doses of Sputnik Light booster against coronavirus have been shipped to Venezuela becoming the biggest one-time global delivery of the one-shot vaccine.
  • Sputnik Light is based on human adenovirus serotype 26 (the first component of Sputnik V).
  • Recent preliminary study announced by Gamaleya Institute showed that Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron.
  • Sputnik V standalone also induces robust neutralizing antibody response to Omicron variant, which is further strengthened by Sputnik Light booster.

Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (2021 to 2030) - Industry Trends and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 12, 2021
Biotechnology, Pharmaceutical, Genetics, Health, Gamaleya Research Institute of Epidemiology and Microbiology, Gene, COVID-19, Partnership, AZD1222, AstraZeneca, Coronavirus, Organization, Efficiency, Development, Technology, Geography, WHO, Severe acute respiratory syndrome coronavirus 2, Sputnik V COVID-19 vaccine, Vaccine, Therapy

The "Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, and Geographical Regions: Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, and Geographical Regions: Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • This report features an extensive study of the rapidly growing market of vector and gene therapy manufacturing, focusing on contract manufacturers, as well as companies having in-house manufacturing facilities.
  • At present, several innovator companies are actively engaged in developing / producing viral and / or non-viral vectors for gene therapies.
  • Given the growing demand for interventions that require genetic modification, the vector and gene therapy manufacturing market is poised to witness substantial growth in the foreseen future.

RDIF: Laboratorios Richmond to provide Argentina with over 3 million doses of the second component of the Sputnik V vaccine in August with the first 150,000 doses to become available for vaccination this week

Retrieved on: 
Tuesday, August 3, 2021
Adenoviridae, Clinical trials, Vaccine controversies, Medicine, Gamaleya Research Institute of Epidemiology and Microbiology, Science and technology in Russia, Sputnik V COVID-19 vaccine, Vaccination, Health sciences, COVID-19 vaccination in Vietnam, COVID-19 vaccination in Algeria

Laboratorios Richmond is expected to produce over 3 million doses of the second component of Sputnik V in August.

Key Points: 
  • Laboratorios Richmond is expected to produce over 3 million doses of the second component of Sputnik V in August.
  • This week the Company will start supplying the Government of Argentina with locally produced Sputnik V vaccine including 150,000 doses of the second component to protect the population.
  • Argentina was the first country in Latin America both to authorize Sputnik V and to start its production.
  • To date, the Sputnik V vaccine has been registered in 69 countries globally with a total population of over 3.7 bn people.

Swedish company ZandCell offers Russia 750 million dose vaccine capacity for Sputnik V and Aurora

Retrieved on: 
Thursday, July 29, 2021
COVID-19 pandemic in Russia, COVID-19 vaccines, Clinical trials, Medicine, Gamaleya Research Institute of Epidemiology and Microbiology, Science and technology in Russia, Vaccination, Sputnik V COVID-19 vaccine, Mass media, Sputnik, COVID-19 vaccine, COVID-19 vaccination in India

"We want either Sputnik V vaccine from Gamaleya or Aurora from Vector Institute.

Key Points: 
  • "We want either Sputnik V vaccine from Gamaleya or Aurora from Vector Institute.
  • I believe Sputnik V is the best vaccine in the world right now.
  • We are ready to manufacture 750 million doses per year and we offer our capacity to Russia.
  • For more information on ZandCell email: [email protected]
    Please visit the company's website at ZandCell.com or follow @ZandCell on Twitter.

Sputnik V vaccine elicits high IGG antibodies and neutralizing antibodies titers, a study in Argentina published in international Cell Reports Medicine journal shows

Retrieved on: 
Monday, July 12, 2021
COVID-19 vaccines, Vaccines, Clinical trials, Vaccination, Medicine, COVID-19 pandemic in Russia, Science and technology in Russia, Gamaleya Research Institute of Epidemiology and Microbiology, Sputnik V COVID-19 vaccine, Sputnik Light, COVID-19, Immunoglobulin G

The study has been published in an international peer-reviewed, open access Cell Reports Medicine journal: https://www.sciencedirect.com/science/article/pii/S2666379121002081

Key Points: 
  • The study has been published in an international peer-reviewed, open access Cell Reports Medicine journal: https://www.sciencedirect.com/science/article/pii/S2666379121002081
    The research evaluates SARS-CoV-2-specific antibody responses after vaccination of 288 healthcare workers with Sputnik V in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses among non-infected and previously infected individuals.
  • Among key findings in the article they note that the first dose of Sputnik V induced strong immune response in 94% of individuals previously not infected with COVID.
  • In authors' opinion, vaccination with only the first component of Sputnik V (Sputnik Light vaccine) is sufficient to protect previously infected individuals.
  • To date, Sputnik V has been registered in 67 countries globally with a total population of over 3.5 billion people.

Top American doctors and medical workers take part in a first briefing on the Sputnik V vaccine in the United States by Russia's Gamaleya Center scientists

Retrieved on: 
Tuesday, September 29, 2020
Health, Medicine, Vaccines, Gam-COVID-Vac, Vaccine, Clinical trial, Coronavirus disease, COVID-19 vaccine, Gamaleya Research Institute of Epidemiology and Microbiology

All the medical professionals who took part in the briefing have had extensive practical experience of COVID-19 treatment in recent months.

Key Points: 
  • All the medical professionals who took part in the briefing have had extensive practical experience of COVID-19 treatment in recent months.
  • The Gamaleya Center scientists told the U.S. audience in detail about the key stages of the development of Sputnik V, including the results of earlier clinical trials and the progress of an ongoing post-registration clinical trial.
  • Post-registration clinical trials of the Sputnik V vaccine involving 40,000 volunteers are currently ongoing.
  • If the vaccine performs as the data suggests, you have a very good vaccine on your hands.